ASEA 23
MINNEAPOLIS, MN
APRIL 26-28, 2023
Corporate Program
Gain visibility into your data and the possibilities will emerge.

For over 40 years, Terumo Blood and Cell Technologies has been providing expertise, data, and technology for our customers. We are pleased to offer Veda Solutions — an expanded suite of collaborative offerings empowering you to improve your cell collection performance.

Visit our booth to learn more.
CORPORATE SUPPORTERS

ASFA wishes to acknowledge the support of all companies and organizations that contributed generously to the ASFA 2023 Annual Meeting.

PLATINUM LEVEL SUPPORTER:

TERUMO
BLOOD AND CELL TECHNOLOGIES

GOLD LEVEL SUPPORTER:

Mallinckrodt Pharmaceuticals

BRONZE LEVEL SUPPORTER:

FRESENIUS KABI
caring for life

SYMPOSIA AND FOCUS GROUP SUPPORTERS:

BIOLINE RX sanofi TERUMO
BLOOD AND CELL TECHNOLOGIES
WEDNESDAY, APRIL 26, 2023

8:00am – 4:30pm  Exhibit Hall Move In

12:00pm – 1:00pm  Corporate Lunch Symposium

**Supported by Sanofi**

(Open to all registered delegates - arrive early as seating is limited)

**aTTP/iTTP Treatment and ISTH Guidelines**

Join us for an engaging discussion on aTTP/iTTP and available treatment options for the disease.

**Speaker 1: Dr. Gustaaf de Ridder, MD, PhD,** System Director of Transfusion Services and Director of Apheresis and Patient Blood Management at Geisinger Health System in Pennsylvania.

**Learning Objectives:**
- Provide an overview of aTTP/iTTP, including pathophysiology, epidemiology, patient presentation, disease burden, and diagnosis
- Understand the importance of rapid diagnosis and immediate treatment due to acute nature and high mortality of aTTP/iTTP disease if left untreated
- Discuss available treatment options for aTTP/iTTP
- Review the ISTH Guidelines and their recommendation on Diagnosis and Treatment Approaches for TTP.

**Speaker 2: Leticia Gonzalez,** Director of Institutional Accounts Teams at Sanofi. Speaker 2 will provide a short overview of Sanofi Promise, a warranty program for aTTP/iTTP treatment, after Dr. De Ridder concludes his session.

6:15pm – 8:00pm  Welcome Reception in Exhibit & Poster Hall

THURSDAY, APRIL 27, 2023

10:00am – 6:30pm  Exhibit & Poster Hall Open

10:15am – 10:45am  Break in Exhibit & Poster Hall

12:30pm – 1:30pm  Corporate Lunch Symposium

**Supported by Sanofi**

(Open to all registered delegates - arrive early as seating is limited)

**Advances in iTTP Management – Contemporary Clinical Approaches**

Join the Sanofi medical affairs symposium to gain insights from a panel of experts on how to prioritize clinical management of aTTP/iTTP, focusing on early treatment, preventing organ damage, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes.

**Speakers: Dr. Camila Masias,** Baptist Hospital of Miami & **Dr. Marshall A. Mazepa,** University of Minnesota Health Cancer Clinic

The symposium will be presented in two parts:
- Part 1 will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, facets of pathology and corresponding treatment axes, before discussing the ISTH guidelines on diagnosis and treatment of iTTP
- Part 2 will review the rationale and the recently revised iTTP outcome definitions (clinical response, exacerbation, remission, and relapse) by the International Working Group (IWG 2021), the important implications on clinical management of iTTP, and finishing with two case vignettes to understand real-world application of these new practices.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Lunch in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>3:15pm – 3:45pm</td>
<td>Break in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>5:30pm – 6:30pm</td>
<td>Poster Networking Evening in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
</tbody>
</table>

**FRIDAY, APRIL 28, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am – 4:30pm</td>
<td>Exhibit &amp; Poster Hall Open</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>10:15am – 10:45am</td>
<td>Break in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Lunch in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>3:45pm – 4:15pm</td>
<td>Break in Exhibit &amp; Poster Hall</td>
<td>Depot Pavilion</td>
</tr>
<tr>
<td>4:30pm – 8:00pm</td>
<td>Exhibit Hall Move Out</td>
<td>Depot Pavilion</td>
</tr>
</tbody>
</table>

**VISIT US AT BOOTH #9**
EXHIBITOR FLOORPLAN

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexion</td>
<td>17</td>
</tr>
<tr>
<td>BD</td>
<td>7</td>
</tr>
<tr>
<td>Be The Match BioTherapies</td>
<td>22</td>
</tr>
<tr>
<td>Bioline RX</td>
<td>3</td>
</tr>
<tr>
<td>Curate Biosciences</td>
<td>6</td>
</tr>
<tr>
<td>Fresenius Kabi LLC</td>
<td>26</td>
</tr>
<tr>
<td>Kaneka Medical America LLC</td>
<td>18</td>
</tr>
<tr>
<td>Machaon Diagnostics</td>
<td>5</td>
</tr>
<tr>
<td>Mallinckrodt Medical Affairs</td>
<td>4</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Miltenyi Biotec</td>
<td>19</td>
</tr>
<tr>
<td>Sanofi</td>
<td>2</td>
</tr>
<tr>
<td>Terumo</td>
<td>1</td>
</tr>
<tr>
<td>UC San Diego Health</td>
<td>24</td>
</tr>
<tr>
<td>University of Virginia</td>
<td>23</td>
</tr>
</tbody>
</table>
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Alexion, AstraZeneca Rare Disease

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 70,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com

BioLineRx is a pre-commercial stage biopharmaceutical company focused on oncology and areas of high unmet need. BioLineRx has pipeline programs in stem cell mobilization for multiple myeloma; pancreatic cancer; and solid tumors. BioLineRx is based in Tel Aviv and Waltham, MA.

At Curate Biosciences we see a future where patients, clinicians, innovators, and payors routinely embrace cell and gene therapies against intractable disease.

To help make this future a reality, we focus on advancing our platform technology, Deterministic Cell Separation™, to deliver greater quantities of the highest quality cellular starting materials, faster and less costly, to the innovators, developers, and clinicians pushing the boundaries of the possible.

The Curate® Cell Processing System gently isolates leukocytes using Deterministic Cell Separation™ (DCS), an advanced, high-speed microfluidic technology that gently separates cells based on size. Optimized for processing apheresis and cell culture samples, the Curate obtains uniquely larger quantities of healthier leukocytes compared to other separation technologies.
FRESENIUS KABI

caring for life

Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies. Known as a leader in transfusion medicine, the company offers a comprehensive portfolio of medical technologies for therapeutic apheresis and blood collection. The people of Fresenius Kabi are driven by a common purpose: to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face.

KANEKA MEDICAL AMERICA, LLC

Kaneka Medical America (KMA) is a wholly owned subsidiary of Kaneka Americas Holdings, Inc. Established in 1997, KMA, with main office located in New York, NY, is the exclusive distributor in the U.S. and Canada for the extracorporeal Lipoprotein Apheresis system, LIPOSORBER®, manufactured by Kaneka Corporation. It is the only Lipoprotein Apheresis therapy approved by FDA for the following two patient populations:

1. Clinically diagnosed Familial Hypercholesterolemic patients with either documented CAD or PAD, if LDL-C > 100mg/dl -or- Lp(a) > 60 mg/dl and LDL-C > 100 mg/dl when diet and maximum tolerable combination lipid-lowering drug therapies have failed to achieve the established therapeutic targets per professional guidelines.

2. Adult and pediatric patients with nephrotic syndrome associated with primary FSGS when:
   - Standard treatment options, including corticosteroids and/or calcineurin inhibitor treatments, are unsuccessful or not well tolerated and the patient's GFR > 60 ml/min/1.73 m²
   - The patient is post renal transplantation

MACHON DIAGNOSTICS

Founded in 2003, Machaon Diagnostics is a CAP and CLIA-accredited, multi-state licensed (including NY) clinical reference laboratory and Rare Disease Contract Research Organization (CRO). We are experts in coagulation, platelet, complement, genetic and rare disease testing services. We are often the fastest option in critical clinical situations where turnaround time matters most. We service the clinical needs of physicians, hospitals and healthcare systems across the US and in 20 countries. Our clinical trial services are provided to pharmaceutical and biotechnology companies around the globe. Ask us why 9 of the 10 top academic medical centers, 8 of the 10 largest pharma/biotech firms and 8 of the 10 largest global CROs in the world choose to hire Machaon for their most challenging projects. Visit MachaonDiagnostics.com to view our complete list of therapeutic areas and learn more about how we can help you.

MALLINCKRODT PHARMACEUTICALS

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

MILTENYI BIOTEC

Miltényi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from
basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries — all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

Sanofi’s global specialty care business unit focuses on rare diseases, rare blood disorders, neurology, immunology, and oncology leveraging science and innovation to help improve people’s lives. www.sanofi.us

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. TERUMOBCT.COM

UC San Diego Health

UC San Diego Health has one of the largest therapeutic apheresis programs in the United States. It is the only center in the San Diego region that offers outpatient therapeutic apheresis services. Directed by Amber Sanchez, MD, our team is experienced with the most advanced and effective apheresis treatment protocols to ensure the highest quality of care.

Faculty of the Apheresis Program of UC San Diego Health make a direct and significant contribution to numerous clinical research studies taking place here and collaborating medical institutions.

UC San Diego Health offers:
- The only photopheresis and LDL apheresis in San Diego County
- The largest hematopoietic stem cell (HSC) collection facility in San Diego County
- Onsite physician presence during treatment
- Latest state-of-the-art technology
- Treatment for:
  - Plasmapheresis
  - Photopheresis
  - LDL Apheresis
  - Red Cell Exchange Apheresis
  - White Cell Reduction Apheresis
  - Platelet Reduction Apheresis
  - Hematopoietic Stem Cell Harvest Apheresis

The Therapeutic Apheresis Academy is a multidisciplinary 2½ day course for physicians in nephrology, hematology, pathology/blood banking, and other allied health professionals with an interest in therapeutic apheresis. This conference will build upon previously established interprofessional learning using modern learning techniques. The main sessions will present an overview of current practice and information on building a new therapeutic apheresis service. The demonstration workshops will showcase clinical applications and provide an opportunity to glean practical tips from expert practitioners.
ASFA 24
APRIL 17–19, 2024 // LAS VEGAS, NV

An Educational and Networking Forum For Professionals in the Field of Apheresis Medicine

- Propose a Session
- Recommend a Speaker
- Submit an Abstract
- Register to Attend
- Reserve Your Exhibit Space
- Book Your Corporate Symposium or Focus Group

PROGRAM FORMAT:
- Scientific Symposia
- Education Sessions
- Oral & Poster Presentations
- Interactive Case Studies & Discussion
- Receptions
- Committee Meetings
- Corporate Symposia & Focus Groups
- Exhibit Hall

EARN CME, CMLE, & CEU CREDITS

WWW.APHERESIS.ORG

ASFA 2023 CONFERENCE SECRETARIAT
Malachite Management Inc
1618 Station St, Vancouver, BC, Canada V6A 1B6
E. asfa@apheresis.org T. 604.484.2851 F. 604.874.4378